170 related articles for article (PubMed ID: 29570686)
1. Design, Synthesis, and Biological Evaluation of Axitinib Derivatives.
Wei N; Liang J; Peng S; Sun Q; Dai Q; Dong M
Molecules; 2018 Mar; 23(4):. PubMed ID: 29570686
[TBL] [Abstract][Full Text] [Related]
2. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
Miyazaki A; Miyake H; Fujisawa M
Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
[TBL] [Abstract][Full Text] [Related]
4. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Goldstein R; Pickering L; Larkin J
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
[TBL] [Abstract][Full Text] [Related]
5. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
6. Two anti-angiogenic TKI-PET tracers, [(11)C]axitinib and [(11)C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents.
Slobbe P; Poot AJ; Haumann R; Schuit RC; Windhorst AD; van Dongen GA
Nucl Med Biol; 2016 Oct; 43(10):612-24. PubMed ID: 27497236
[TBL] [Abstract][Full Text] [Related]
7. Axitinib for renal cell carcinoma.
Sonpavde G; Hutson TE; Rini BI
Expert Opin Investig Drugs; 2008 May; 17(5):741-8. PubMed ID: 18447599
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity.
Elsayed NMY; Serya RAT; Tolba MF; Ahmed M; Barakat K; Abou El Ella DA; Abouzid KAM
Bioorg Chem; 2019 Feb; 82():340-359. PubMed ID: 30428414
[TBL] [Abstract][Full Text] [Related]
9. Axitinib in metastatic renal cell carcinoma.
Albiges L; Gizzi M; Carton E; Escudier B
Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
[TBL] [Abstract][Full Text] [Related]
10. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
Zakharia Y; Zakharia K; Rixe O
Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
[TBL] [Abstract][Full Text] [Related]
11. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.
Lu L; Saha D; Martuza RL; Rabkin SD; Wakimoto H
J Neurooncol; 2015 Jan; 121(1):91-100. PubMed ID: 25213669
[TBL] [Abstract][Full Text] [Related]
12. The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.
Heine A; Held SA; Daecke SN; Riethausen K; Kotthoff P; Flores C; Kurts C; Brossart P
PLoS One; 2015; 10(6):e0128897. PubMed ID: 26042424
[TBL] [Abstract][Full Text] [Related]
13. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel taspine derivatives as antiangiogenic agents.
Zhang J; Zhang Y; Zhang S; Wang S; He L
Bioorg Med Chem Lett; 2010 Jan; 20(2):718-21. PubMed ID: 20006929
[TBL] [Abstract][Full Text] [Related]
15. In silico discovery of potential VEGFR-2 inhibitors from natural derivatives for anti-angiogenesis therapy.
Li J; Zhou N; Luo K; Zhang W; Li X; Wu C; Bao J
Int J Mol Sci; 2014 Sep; 15(9):15994-6011. PubMed ID: 25216334
[TBL] [Abstract][Full Text] [Related]
16. Axitinib for the treatment of advanced renal cell carcinoma.
Akaza H; Fukuyama T
Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
[TBL] [Abstract][Full Text] [Related]
17. Axitinib in the treatment of metastatic renal cell carcinoma.
Ho TH; Jonasch E
Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
[TBL] [Abstract][Full Text] [Related]
18. Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells.
Morelli MB; Amantini C; Santoni M; Soriani A; Nabissi M; Cardinali C; Santoni A; Santoni G
Oncotarget; 2015 Nov; 6(34):36245-59. PubMed ID: 26474283
[TBL] [Abstract][Full Text] [Related]
19. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation.
Yuan H; Cai P; Li Q; Wang W; Sun Y; Xu Q; Gu Y
Biomed Pharmacother; 2014 Jul; 68(6):751-6. PubMed ID: 25081318
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of pazopanib derivatives as antitumor agents.
Jia Y; Zhang J; Feng J; Xu F; Pan H; Xu W
Chem Biol Drug Des; 2014 Mar; 83(3):306-16. PubMed ID: 24119291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]